Think if you even exclude Acne, you can look at AD and their anti-biotic development line...
Yeah, they will need to raise for Ph3, but that won't be until at least Ph2 results are out for AD. I assume they will look at both, then decide which is the best to take forward.
Well, that would seem the most logical to me. Makes me wonder if that was why they stacked AD and Acne results so close to each other, assuming one doesn't meet target the other may.
AD also has a bigger market share. From what I understand.
I know it sounds pretty ambitious at this point, but there is data for our other products which looks promising.
Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-488
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |